Miklos Gaszner, M.D., Ph.D.


Miklos Gaszner combines a deep understanding of biosciences and patent law to build strong patent portfolios for his clients.

Nixon Vanderhye Shareholder Miklos Gaszner, M.D., Ph.D., advises biotechnology and pharmaceutical companies on the development and execution of global patent strategy. He is skilled in U.S. and international patent procurement, invalidity, non-infringement, and patentability opinions, as well as freedom-to-operate and due diligence investigations.

Miklos has deep technical experience in the following areas:

  • Therapeutic Antibodies, including antibody engineering, production, and formulation
  • Cancer Treatment, including immuno oncology therapies and cancer vaccines
  • HIV Vaccines
  • RNA-Based Therapeutics, including antisense RNAs and therapeutic mRNAs
  • Recombinant Microorganisms
  • Metabolic Engineering
  • Influenza Vaccines
  • Food Supplements

Prior to entering private practice, Miklos worked in-house as a patent agent at MedImmune LLC (now part of AstraZeneca), and was most recently a director at a prominent intellectual property law firm based in Washington, D.C.

Miklos received a Ph.D. in Molecular Biology from Princeton University. His research focused on chromatin structure and eukaryotic transcriptional control.

  • Patents
    • Preparation and Prosecution
    • Post-Grant Proceedings
    • Due Diligence
    • Domestic and Worldwide Portfolio Management
    • PTAB Practice
    • Opinions & Counseling
  • IP Transactions, Agreements, and Trade Secrets
    • Licensing, Sales, and Assignments
    • Non-Disclosure Agreements
    • Due Diligence
  • Biotechnology
    • Therapeutic
      • Therapy
        • Protein based therapeutics
          • Biotherapeutics (biologics and biosimilars)
          • Antibody based drugs
          • Antibody mimetics
          • Peptide drugs
          • Vaccines
        • Nucleic acid based therapeutics
          • RNA and RNA analogue therapeutics
          • DNA and DNA analogue therapeutics
          • Gene therapy
          • Genome editing
        • Cell based therapeutics
          • Tissue engineering and regeneration
          • Cell engineering
          • Immune therapeutics
          • Microbiome based therapeutics
        • Stem cell, progenitor, and primary cell therapeutics
        • Regenerative therapeutics
        • Targeted therapeutics
        • Drug discovery, delivery, and formulation platforms
      • Manufacturing
        • Upstream bioprocessing (cell culture, bioreactor and fermentation technology)
        • Downstream bioprocessing (purification)
        • Formulation
      • Diagnostics
        • Protein based diagnostics technologies
        • Nucleic acid based diagnostics
        • Precision medicine
        • Theranostics
        • Pharmacogenomics
        • Companion diagnostics
      • Medical devices
    • Industrial and Agricultural Biotechnology
      • Synthetic biology
      • Protein engineering
      • Biocatalysts (enzymes and microorganisms)
      • Bioprocessing (bioreactor and fermentation technology)
      • Plant and microorganism metabolic engineering
      • Genetically modified organisms (microorganisms, plants, and animals)
      • Bio based products (chemicals, monomers, polymers, and gasses)
      • Green and clean technology
    • Nutraceuticals
  • Pharmaceuticals
    • New Chemical Entities
      • Synthetic compounds
      • Natural products and derivatives
    • Drug Repositioning
      • Prodrugs
      • Combinations
      • New indications
      • New pharmacokinetics
      • Targeted drug delivery
      • Precision medicine
    • Manufacturing
      • Synthetic chemistry
      • Polymorphs and co-crystals
      • Purification
      • Formulation
    • Drug Discovery and development tools
      • Combinatory chemistry
      • Drug screening assays
      • Drug design platforms
      • Catalysis and reactors
  • Chemical, Industrial & Material Science
    • Food and beverages
      • Dietary supplements
      • Food additives
    • Nanotechnology
    • Polymers
    • 3-D Printing
    • Organometallics
    • Cosmetics
    • Herbicides and pesticides
    • Analytical chemistry
    • Ceramics
  • Maryland
  • District of Columbia
  • U.S. Patent and Trademark Office
  • J.D., magna cum laude, American University, Washington College of Law, 2011
  • Ph.D. in Molecular Biology, Princeton University, 1999
  • M.D., summa cum laude, Albert Szent-Gyorgyi Medical University, Hungary, 1992
  • Co-Author, “Patenting the Plant Microbiome,” Industrial Biotechnology, pp.123-125, 2018.
  • Co-Author, “Are Your Claims Patent Eligible?” Biofuels International, pp. 52-54, July/August 2015.
  • Co-Author, “Inter Partes Review - One Year Later,” Euro Biotech News, p. 14, 2014.
  • Co-Author, “Insulators: Exploiting Transcriptional and Epigenetic Mechanisms,” Nature Reviews Genetics, pp. 703-713, September 2006.
  • Co-Author, “Recruitment of Histone Modifications by USF proteins at a Vertebrate Barrier Element,” Molecular Cell, pp. 453-463, Nov. 5, 2004.
  • Co-Author, “Correlation Between Histone Lysine Methylation and Developmental Changes at the Chicken Beta-Globin Locus,” Science, pp. 2453-2455, Sept. 28, 2001.

Get To Know Miklos

What are your hobbies?


What would your perfect day include?

Spending time with my wife and two sons exploring the great outdoors.

What would friends surprised to learn about you?

I love cooking for friends.